1082554--2/27/2006--UNITED_THERAPEUTICS

related topics

{product, candidate, development}

{product, liability, claim}

{stock, price, operating}

{stock, price, share}

{personnel, key, retain}

{provision, law, control}

{cost, regulation, environmental}

{property, intellectual, protect}

{regulation, change, law}

Actual consolidated revenues and net income may be different from published securities analyst projections. In addition, we have a history of losses and may not continue to be profitable. We may not successfully compete with established drugs and the companies that develop and market them. Discoveries or developments of new technologies by others may make our products obsolete or less useful. We are aware of investigational products being developed for the treatment of PAH with which our products may have to compete. If third-party payers will not reimburse patients for our drug products or if third-party payers limit the amount of reimbursement, our sales will suffer. We rely on third parties to develop, market, distribute and sell most of our products and those third parties may not perform. If we cannot maintain regulatory approvals for our products, we cannot sell those products and our revenues will suffer. Our products may not be commercially successful because physicians and patients may not accept them. We have limited experience with manufacturing and depend on third parties, who may not perform, to synthesize and manufacture many of our products. If our products fail in clinical studies, we will not be able to obtain or maintain FDA and foreign approvals and will not be able to sell those products. Our corporate compliance program cannot guarantee that we are in compliance with all potentially applicable federal, state and foreign regulations. If the licenses, assignments and alliance agreements we depend on are breached or terminated, we would lose our right to develop and sell the products covered by the licenses, assignments and alliance agreements. Certain license and assignment agreements relating to our products may restrict our ability to develop products in certain countries and/or for particular diseases and impose other restrictions on our freedom to develop and market our products. If our patent and other intellectual property protection is inadequate, our sales and profits could suffer or competitors could force our products completely out of the market. If our highly qualified management and technical personnel leave us, our business may suffer. We may not have adequate insurance and may have substantial exposure to payment of product liability claims. We may not have, or may have to share rights to, future inventions arising from our license, assignment and alliance agreements and may lose potential profits or savings. If we need additional financing and cannot obtain it, product development and sales may be limited. Our activities involve hazardous materials, and improper handling of these materials could expose us to significant liabilities. Our stock price could be volatile and could decline. Future sales of shares of our common stock may depress our stock price. Provisions of Delaware law and our certificate of incorporation, by-laws and shareholder rights plan could prevent or delay a change of control or change in management that could be beneficial to us and our public stockholders. Our existing directors and executive officers own a substantial block of our stock and might be able to influence the outcome of matters requiring stockholder approval. If stockholders do not receive dividends, stockholders must rely on stock appreciation for any return on their investment in us.

Full 10-K form ▸

1082554--2/27/2006--UNITED_THERAPEUTICS_CORP